Margaret Pax Buys 250 Shares of Repligen Co. (NASDAQ:RGEN) Stock

Repligen Co. (NASDAQ:RGEN) Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Repligen Price Performance

RGEN opened at $144.34 on Wednesday. The stock’s 50-day moving average price is $156.98 and its 200 day moving average price is $148.49. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $200.23. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.09 billion, a price-to-earnings ratio of -283.02, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

A number of hedge funds have recently bought and sold shares of RGEN. Signaturefd LLC raised its position in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. acquired a new stake in shares of Repligen during the 4th quarter worth about $29,000. Raiffeisen Bank International AG acquired a new stake in shares of Repligen during the 4th quarter worth about $29,000. Resources Management Corp CT ADV acquired a new stake in shares of Repligen during the 3rd quarter worth about $37,000. Finally, Quarry LP raised its position in shares of Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 239 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their price target on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a research note on Tuesday. They set an “in-line” rating and a $155.00 target price for the company. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.